SAB Biotherapeutics (SABS) could surge 150%
On Monday, November 1st, at 16:18, Baird analyst Coleen Kusy, initiated coverage of SAB Biotherapeutics (SABS) with an Outperform rating and a $23 price target. This seems to have caused the price to surge afterhours and I’m sure more people…